Clinical Laserthermia Systems AB (publ) develops and markets therapies, systems, and single-use instruments for thermal treatment of solid cancer tumors in Sweden.
+ 2 more risks
Worrying balance sheet with weak fundamentals.
Share Price & News
How has Clinical Laserthermia Systems's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CLS B's share price has been volatile over the past 3 months.
7 Day Return
SE Medical Equipment
1 Year Return
SE Medical Equipment
Return vs Industry: CLS B underperformed the Swedish Medical Equipment industry which returned 12.4% over the past year.
Return vs Market: CLS B underperformed the Swedish Market which returned -11.6% over the past year.
Price Volatility Vs. Market
How volatile is Clinical Laserthermia Systems's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StDid You Manage To Avoid Clinical Laserthermia Systems's (STO:CLS B) 39% Share Price Drop?
2 months ago | Simply Wall StCould The Clinical Laserthermia Systems AB (publ) (STO:CLS B) Ownership Structure Tell Us Something Useful?
3 months ago | Simply Wall StIs Clinical Laserthermia Systems (STO:CLS B) Using Too Much Debt?
Is Clinical Laserthermia Systems undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CLS B's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CLS B's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CLS B is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: CLS B is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CLS B's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CLS B is overvalued based on its PB Ratio (18.1x) compared to the SE Medical Equipment industry average (3.6x).
How is Clinical Laserthermia Systems forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLS B is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CLS B is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CLS B is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if CLS B's revenue is forecast to grow faster than the Swedish market.
High Growth Revenue: Insufficient data to determine if CLS B's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLS B is forecast to be unprofitable in 3 years.
How has Clinical Laserthermia Systems performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CLS B is currently unprofitable.
Growing Profit Margin: CLS B is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CLS B is unprofitable, and losses have increased over the past 5 years at a rate of -15.5% per year.
Accelerating Growth: Unable to compare CLS B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLS B is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.6%).
Return on Equity
High ROE: CLS B has a negative Return on Equity (-526.05%), as it is currently unprofitable.
How is Clinical Laserthermia Systems's financial position?
Financial Position Analysis
Short Term Liabilities: CLS B's short term assets (SEK12.5M) do not cover its short term liabilities (SEK30.0M).
Long Term Liabilities: CLS B's short term assets (SEK12.5M) exceed its long term liabilities (SEK608.0K).
Debt to Equity History and Analysis
Debt Level: CLS B's debt to equity ratio (261%) is considered high.
Reducing Debt: CLS B's debt to equity ratio has increased from 0.2% to 261% over the past 5 years.
Inventory Level: CLS B has a low level of unsold assets or inventory.
Debt Coverage by Assets: CLS B's debt is not covered by short term assets (assets are 0.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CLS B has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CLS B has less than a year of cash runway if free cash flow continues to reduce at historical rates of -13.6% each year
What is Clinical Laserthermia Systems's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CLS B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CLS B's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CLS B's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CLS B's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CLS B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Mr. Lars-Erik T. Eriksson serves as the Chief Executive Officer and Director of Clinical Laserthermia Systems AB (publ). Mr. Eriksson earned MBA in Economics From Lund University in the year 1975 to 1975.
CEO Compensation Analysis
Compensation vs Market: Lars-Erik's total compensation ($USD0.00) is below average for companies of similar size in the Swedish market ($USD214.61K).
Compensation vs Earnings: Insufficient data to compare Lars-Erik's compensation with company performance.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.
Clinical Laserthermia Systems AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Clinical Laserthermia Systems AB (publ)
- Ticker: CLS B
- Exchange: OM
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr190.694m
- Shares outstanding: 45.46m
- Website: https://www.clinicallaser.se
- Clinical Laserthermia Systems AB (publ)
- Medicon Village
- Scheelevägen 2
- Skåne County
- 223 81
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CLS B||OM (OMX Nordic Exchange Stockholm)||Yes||Class B Shares||SE||SEK||Apr 2009|
|LS6||DB (Deutsche Boerse AG)||Yes||Class B Shares||DE||EUR||Apr 2009|
Clinical Laserthermia Systems AB (publ) develops and markets therapies, systems, and single-use instruments for thermal treatment of solid cancer tumors in Sweden. The company offers TRANBERG, a cancer immunotherapy system that includes a laser unit with unique monitoring capabilities and tailored single-use products primarily developed for imILT treatment; and applicator kit. It also is developing products for the treatment of breast, pancreatic, skin, and prostate cancers, as well as other solid cancer tumors. Clinical Laserthermia Systems AB (publ) has a collaboration agreement with Image Guided Therapy SA to develop and commercialize a software product for MR-generated temperature monitoring; and a collaborative license and co-development agreement with MRI Interventions, Inc. to provide navigation and laser ablation platforms for use in spine and neurosurgery. The company is headquartered in Lund, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/02 21:35|
|End of Day Share Price||2020/04/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.